论文部分内容阅读
目的探讨米非司酮治疗子宫腺肌症效果及小剂量长期用药的安全性。方法62例子宫肌腺症患者开始全部接受短期治疗,口服米非司酮25mg/d,总疗程6个月。观察患者症状、体征、血红蛋白、子宫体积、内膜厚度的变化。复发病例16例接受长期治疗、方案为口服米非司酮12.5mg/d持续用药。结果服药期间所有患者均闭经,痛经消失。短期治疗结束后,贫血纠正,子宫体积明显缩小,内膜变薄。年轻患者停药后复发率高于围绝经期患者。复发者,进行长期治疗仍有效。结论米非司酮治疗子宫肌腺症安全、有效。
Objective To investigate the efficacy of mifepristone in the treatment of adenomyosis and the safety of small doses of long-term medication. Methods 62 cases of myasthenia gravis patients began receiving all short-term treatment, oral mifepristone 25mg / d, the total course of 6 months. Observe the patient’s symptoms, signs, hemoglobin, uterine volume, changes in intima thickness. 16 cases of recurrent cases received long-term treatment, the program for oral mifepristone 12.5mg / d continued medication. Results All patients underwent amenorrhea during menstruation, dysmenorrhea disappeared. After short-term treatment, anemia correction, significantly reduced uterine volume, thinning of the intima. Young patients relapse rate after stopping than perimenopausal patients. Recurrence, long-term treatment is still valid. Conclusion Mifepristone is safe and effective in the treatment of adenomyosis.